Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1997-11-21
2000-09-12
Davis, Zinna Northington
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
A61K 3116
Patent
active
061179019
ABSTRACT:
Disclosed are compounds which inhibit .beta.-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits .beta.-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
REFERENCES:
patent: 3657341 (1972-04-01), Thorne
patent: 3876683 (1975-04-01), Vincent et al.
patent: 4666829 (1987-05-01), Glenner et al.
Doherty, et al., The Resolution of Amino Acids by Asymmetric Enzymatic Synthesis, J. Biol. Chem., 189:447-454 (1951).
Pazhanisamy, et al., .beta.-Lactamase-Catalyzed Amnolysis of Depsipeptides: Peptide Inhibition and a New Kinetic Mechanism, Biochemistry, 28:6875-6882 (1989).
Ogawa, et al., A New Method for Preparing D-Penicillamine, Reaction of Benzylpenicilloic Acid .alpha.-Amides with Arylamines, Chem. Pharm. Bull., 36(6):1957-1962 (1988).
Cordell, .beta.-Amyloid Formation as a Potential Therapeutic Target for Alzheimer's Disease, Ann. Rev. Pharmacol. Toxicol., 34:69-89 (1994).
Smith, et al., .beta.-APP Processing as a Therapeutic Target for Alzheimer's Disease, 3:439-445 (1997).
Clark, "The Chemistry of Penicillin", Princeton University Press, pp. 240, 708, 786, 795 and 875 (1949).
Papadopoulos, et al., "Anodic Oxidation of N-Acyl and N-Alkoxycarbonyl Dipeptide Esters as a Key Step for the Formulation of Chiral Heterocyclic Synthetic Building Blocks", Tetrahedron, 47(4/5):563-572 (1991).
Waldmann, et al., "Selective Enzymatic Removal of Protecting Groups: The Phenylacetamide as Amino Protecting Group in Phosphopeptide Synthesis", Tetrahedron letters, 37(48):8725-8728 (1996).
Pessina, et al., "Amide-Bond Syntheses Catalyzed by Penicillin Acylase", Helvetica Chimica Acta, 71:631-641 (1988).
Cordell, Barbara, ".beta.-Amyloid Formation as a Potential Therapeutic Target for Alzheimer's Disease", Annu. Rev. Pharmacol. Toxicol. 34, pp. 69-89 (1994).
Smith, et al., ".beta.-APP Processing as a Therapeutic Target for Alzheimer's Disease", Current Pharmaceutical Design, 3(4), pp. 439-445 (1997).
Audia James E.
Fang Lawrence Y.
John Varghese
Latimer Lee H.
Mabry Thomas E.
Athena Neurosciences, Inc.
Davis Zinna Northington
Eli Lilly & Company
LandOfFree
N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical comp does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical comp, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical comp will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-96708